Page 16 - Biomarkers for risk stratification and guidance in heart failure

The prognostic value of a multi-marker strategy for the risk-assessment 1 in dyspneic patients presenting to the emergency department using a panel
of biomarkers with a wide pathophysiological background is investigated in
chapter 2.
Chapter 3 describes the main results of the PRIMA study. This multicenter trial assesses the prognostic effect of natriuretic peptide-guided therapy in chronic HF according to an individually set NT-proBNP level. In chapter 4 insight is given which patients might benefit the most from natriuretic peptide-guided therapy and if comorbidities influence the response to natriuretic peptide-guided therapy. Chapter 5 investigates the prognostic importance of serial NT-proBNP measurements during and shortly after admission because of acute HF. Chapter 6 assesses the prognostic value of change in renal function in addition to change in NT-proBNP early after hospital discharge for acute HF.
Introduction
15